Effectiveness of Atosiban in Women Aged 20 to 40 With Previous Implantation Failure and Abnormal Uterine Contractions Undergoing Single Blastocyst Embryo Transfer

What this Trial Is About

Researchers are evaluating the effect of atosiban in women with infertility who have experienced previous pregnancy failures and abnormal uterine contractions during the time around embryo transfer in assisted reproductive technology. The study aims to see if atosiban improves live birth rates in single blastocyst transfer cycles, whether fresh or frozen-thawed. It also examines differences in perinatal complications, neonatal outcomes, miscarriage rates, and ectopic pregnancy rates. Participants are randomly assigned to receive either atosiban or a placebo. Those in the atosiban group receive an intravenous bolus 30 minutes before embryo transfer, followed by an infusion with a decreasing dose over about two hours. The placebo group receives saline infusions that look identical and last the same length of time. One hour after embryo transfer, uterine contractions are reevaluated by ultrasound. Women with clinical pregnancies are followed up by nurses at 12 and 24 weeks of pregnancy and again about six weeks after delivery to record pregnancy events and outcomes. Those without pregnancy are not followed further. The main outcome measured is live birth after 24 weeks of gestation, with additional assessments including biochemical and clinical pregnancy, miscarriage, stillbirth, ectopic pregnancy, multiple pregnancy, and various newborn health indicators.

Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions